Malcolm Brenner, MD, PhD

Full Affiliate Member, Research Institute
Houston Methodist


Dr. Brenner completed his postdoctoral training in 1981 and joined the Clinical Research Centre of Northwick Park Hospital in London, England as a MRC Clinical Scientist and Honorary Senior Registrar. He also began lecturing in Haematology at the Royal Free Hospital and Hospital for Sick Children, also in London.

Dr. Brenner joined the faculty at the University of Tennessee in Memphis as a Professor in the Departments of Pediatrics and Medicine in 1990. He also became the Director of the Bone Marrow Transplant Division of the St. Jude Children's Research Hospital that same year. He later directed the Cell and Gene Therapy Program at St. Jude's from 1994 until 1997, when he assumed his current positions at the Baylor College of Medicine.

Description of Research

Dr. Brenner's research focuses on gene transfer to stem cells and to effector cells of the immune system. His research group was one of the first to use gene transfer in human subjects, establishing the feasibility of tracking human stem cells and their progeny in subjects with cancer. Dr. Brenner also develops tumor vaccines for pediatric and hematological malignancies, using genetic modification with retroviral and adenoviral vectors.

Areas Of Expertise

Stem cells Gene therapy Cell therapy Vectors
Education & Training

PhD, Cambridge University

Taking T-Cell Oncotherapy Off-the-Shelf
Mo, F, Mamonkin, M, Brenner, MK & Heslop, HE 2021, , Trends in Immunology, vol. 42, no. 3, pp. 261-272.

Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity
McKenna, MK, Englisch, A, Brenner, B, Smith, T, Hoyos, V, Suzuki, M & Brenner, MK 2021, , Molecular Therapy.

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
Ramos, CA, Grover, NS, Beaven, AW, Lulla, PD, Wu, MF, Ivanova, A, Wang, T, Shea, TC, Rooney, CM, Dittus, C, Park, SI, Gee, AP, Eldridge, PW, McKay, KL, Mehta, B, Cheng, CJ, Buchanan, FB, Grilley, BJ, Morrison, K, Brenner, MK, Serody, JS, Dotti, G, Heslop, HE & Savoldo, B 2020, , Journal of Clinical Oncology, vol. 38, no. 32, pp. 3794-3804.

Transgenic CD8aß co-receptor rescues endogenous TCR function in TCR-transgenic virus-specific T cells
Bajwa, G, Lanz, I, Cardenas, M, Brenner, MK & Arber, C 2020, , Journal for immunotherapy of cancer, vol. 8, no. 2, e001487.

Modulating tnfa activity allows transgenic il15-expressing cll-1 car t cells to safely eliminate acute myeloid leukemia
Ataca Atilla, P, McKenna, MK, Tashiro, H, Srinivasan, M, Mo, F, Watanabe, N, Simons, BW, McLean Stevens, A, Redell, MS, Heslop, HE, Mamonkin, M, Brenner, MK & Atilla, E 2020, , Journal for immunotherapy of cancer, vol. 8, no. 2, e001229.

The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma
Lulla, PD, Tzannou, I, Vasileiou, S, Carrum, G, Ramos, CA, Kamble, R, Wang, T, Wu, M, Bilgi, M, Gee, AP, Mukhi, S, Chung, B, Wang, L, Watanabe, A, Kuvalekar, M, Jeong, M, Li, Y, Ketkar, S, French-Kim, M, Grilley, B, Brenner, MK, Heslop, HE, Vera, JF & Leen, AM 2020, , Science translational medicine, vol. 12, no. 554, eaaz3339.

Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma
Hegde, M, Joseph, SK, Pashankar, F, DeRenzo, C, Sanber, K, Navai, S, Byrd, TT, Hicks, J, Xu, ML, Gerken, C, Kalra, M, Robertson, C, Zhang, H, Shree, A, Mehta, B, Dakhova, O, Salsman, VS, Grilley, B, Gee, A, Dotti, G, Heslop, H, Brenner, MK, Wels, WS, Gottschalk, S & Ahmed, N 2020, , Nature Communications, vol. 11, no. 1, 3549.

Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors
Porter, CE, Rosewell Shaw, A, Jung, Y, Yip, T, Castro, PD, Sandulache, VC, Sikora, A, Gottschalk, S, Ittman, MM, Brenner, M & Suzuki, M 2020, , Molecular Therapy, vol. 28, no. 5, pp. 1251-1262.

Engineered off-the-shelf therapeutic T cells resist host immune rejection
Mo, F, Watanabe, N, McKenna, MK, Hicks, MJ, Srinivasan, M, Gomes-Silva, D, Atilla, E, Smith, T, Ataca Atilla, P, Ma, R, Quach, D, Heslop, HE, Brenner, MK & Mamonkin, M 2021, , Nature Biotechnology, vol. 39, no. 1, pp. 56-63.

T-cell receptor stimulation enhances the expansion and function of CD19 chimeric antigen receptor–expressing T cells
Lapteva, N, Gilbert, M, Diaconu, I, Rollins, LA, Al-Sabbagh, M, Naik, S, Krance, RA, Tripic, T, Hiregange, M, Raghavan, D, Dakhova, O, Rouce, RH, Liu, H, Omer, B, Savoldo, B, Dotti, G, Cruz, CR, Sharpe, K, Gates, M, Orozco, A, Durett, A, Pacheco, E, Gee, AP, Ramos, CA, Heslop, H, Brenner, M & Rooney, CM 2019, , Clinical Cancer Research, vol. 25, no. 24, pp. 7340-7350.

Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients
Naik, S, Martinez, CA, Omer, B, Sasa, G, Yassine, K, Allen, CE, Kamdar, K, Orth, R, Wu, M, Leung, K, Gottschalk, S, Brenner, MK, Heslop, H & Krance, RA 2019, , Blood Advances, vol. 3, no. 18, pp. 2689-2695.

Erratum: Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma (Journal of Clinical Investigation (2019) 129:8 (3464) DOI:10.1172/JCI131246)
Hegde, M, Mukherjee, M, Grada, Z, Pignata, A, Landi, D, Navai, SA, Wakefield, A, Fousek, K, Bielamowicz, K, Chow, KKH, Brawley, VS, Byrd, TT, Krebs, S, Gottschalk, S, Wels, WS, Baker, ML, Dotti, G, Mamonkin, M, Brenner, MK, Orange, JS & Ahmed, N 2019, , Journal of Clinical Investigation, vol. 129, no. 8.

Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia
Lulla, PD, Mamonkin, M & Brenner, MK 2019, , Cancer Journal (United States), vol. 25, no. 3, pp. 199-207.

Adoptive Cell Therapy: ACT-Up or ACT-Out?
Brenner, MK 2019, , Molecular Therapy, vol. 27, no. 4, pp. 693-694.

Chimeric antigen receptors for T-cell malignancies
Scherer, LD, Brenner, M & Mamonkin, M 2019, , Frontiers in Oncology, vol. 9, no. MAR, 126.

A phase I/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia
Enblad, G, Karlsson, H, Gammelgård, G, Wenthe, J, Lövgren, T, Amini, RM, Wikstrom, KI, Essand, M, Savoldo, B, Hallböök, H, Höglund, M, Dotti, G, Brenner, M, Hagberg, H & Loskog, A 2018, , Clinical Cancer Research, vol. 24, no. 24, pp. 6185-6194.

EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation
McLaughlin, LP, Rouce, R, Gottschalk, S, Torrano, V, Carrum, G, Wu, MF, Hoq, F, Grilley, B, Marcogliese, AM, Hanley, PJ, Gee, AP, Brenner, M, Rooney, CM, Heslop, H & Bollard, CM 2018, , Blood, vol. 132, no. 22, pp. 2351-2361.

Enhancing the potency and specificity of engineered T cells for cancer treatment
Sukumaran, S, Watanabe, N, Bajgain, P, Raja, K, Mohammed, S, Fisher, WE, Brenner, M, Leen, AM & Vera, JF 2018, , Cancer Discovery, vol. 8, no. 8, pp. 972-987.

CAR T cell therapy for breast cancer: Harnessing the tumor milieu to drive T cell activation
Bajgain, P, Tawinwung, S, DElia, L, Sukumaran, S, Watanabe, N, Hoyos, V, Lulla, P, Brenner, M, Leen, AM & Vera, JF 2018, , Journal for immunotherapy of cancer, vol. 6, no. 1, 34.

Tumor-specific t-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed hodgkin lymphoma
Bollard, CM, Tripic, T, Cruz, CR, Dotti, G, Gottschalk, S, Torrano, V, Dakhova, O, Carrum, G, Ramos, CA, Liu, H, Wu, MF, Marcogliese, AN, Barese, C, Zu, Y, Lee, DY, O’Connor, O, Gee, AP, Brenner, M, Heslop, H & Rooney, CM 2018, , Journal of Clinical Oncology, vol. 36, no. 11, pp. 1128-1139.